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The contamination of soils with lead has
created major remedial, legal, and policy
problems in the United States and through-
out the world. Contributions from industri-
al sources, mining, exterior paints, and lead-
ed gasoline have created numerous sites
where normal hand-to-mouth activity in
children could result in significant lead
ingestion. Across the United States, the
Environmental Protection Agency (EPA)
has found that of the 1300 sites on its
National Priorities List, at least 922 ofthese
sites contain lead (1).
Computer models aimed at estimating
actual exposure use assumptions concerning
lead bioavailability; i.e., the fraction of the
ingested lead dose that enters the blood. We
set out to create a human in vivo model in
which trace quantities oflead in soils or liq-
uids might be ingested and precise, site-spe-
cific estimates of bioavailability could be
derived. Such estimates would greatly
improve the precision of risk assessments.
We chose to develop this model by first
studying the bioavailability of lead in a
matrix somewhat more palatable than soil,
namely, sherrywine.
The bioavailability of lead in wine is a
parameter ofinterest. In 1991, we observed
that the lead concentration ofport wine in
three different decanters rose from 0.43
pmol/l to 10.43, 14.77, and 25.73 pmol/l
(2,3). Alcoholic beverages from decanters in
the homes of our colleagues were found to
contain lead concentrations ranging from
6.77 to 103.90 pmol/l. We wondered why
the literature contains no case reports of
lead toxicity attributable to lead-crystal
glassware and considered the possibility
that the bioavailability of lead in wine
might be exceedingly low.
A host of biological and chemical fac-
tors influence the bioavailability of lead in
humans (4). For example, among adult
volunteers, 9.7% of dietary 204Pb was
absorbed (5). Other studies of radioactive
203Pb in drinking water (without food)
found absorption to range from 60 to 70%
(5); absorption of203Pb in water was less-
ened when ingestion occurred in proximity
to a meal (6). The fraction of lead
absorbed from wine is unknown, but it has
been reported (in animals) that alcohol
facilitates lead absorption (7-9) while tan-
nins inhibit it (10).
Lead has four stable isotopes, 204Pb,
206Pb, 207Pb, and 208Pb, ofwhich the last
three are continually being produced by
radioactive decay. Thus, lead in industrial
use can varygreadyin its stable isotope ratios
according to the geological age of the lead
deposit. For example, the ratio of
206Pb/207Pb in the Broken Hill, Australia,
lead deposit is 1.03; in the younger U.S.
deposits ofthe Mississippi valley, it is as high
as 1.42 (11). We had in our possession a
crystal decanter that had a 206Pb/207Pb ratio
of 1.078, clearly manufactured with lead of
Australian origin. We realized that the
bioavailability of lead in wine or spirits
stored in this decanter could readily be deter-
mined by isotope dilution in American-born
subjects whose 206Pb/207Pb ratios average
approximately 1.200. We further realized
that the bioavailability oflead in any matrix
could be determined by isotope dilution pro-
vided the isotopic ratio ofthe ingested sample
is sufficiently different from that in the blood
of the subjects who ingest it. The advantage
ofthis technique is its extraordinary sensitivi-
ty and precision, which allows one to esti-
mate bioavailability even when the fraction of
lead absorbed is as low as 5%. Thus, we also
examined the blood 206Pb/207Pb ratios of
subjects living in New York, Scotland, and
Australia to develop acadre ofpotential study
volunteers forthis and otherstudies.
Methods
In New York, this study was approved by
the Columbia Presbyterian Medical Center
(CPMC) Institutional Review Board, and
written informed consent was obtained
from each subject. In Glasgow, Scotland,
and in Brisbane, Australia, the sampling of
blood was approved by the Research and
Ethical Committee of the Western
Infirmary and the Ethical Committee of
Princess Alexandra Hospital, respectively.
In NewYork, 61 adult volunteers donat-
ed 10 ml ofblood in response to advertise-
ments posted around the Health Sciences
Campus of Columbia University. In
Glasgow and Brisbane, blood was obtained
from 10 and 12 subjects, respectively.
This was a single dose, nonrandomized,
cross-over study. Ofthe 61 subjects screened
for 206Pb/207Pb in New York, 6 healthy
women and men were chosen who had blood
lead concentrations (BPbs) <0.24 pmol/l and
blood 206Pb/207Pb ratios >1.195. All were
between the ages of21 and 40 years and were
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within 10% of their ideal weight for height
according to the Metropolitan Life Tables.
The six subjects were screened before the
study to assure that theyhad normal urinaly-
ses, blood chemistries, blood counts, and
physical exams. Subjects were admitted to
the Irving Center for Clinical Research (day
1), received a regular hospital dinner, and
were then fasted ovemight, except for water.
At 0600, 0630, and 0700 hr on day 2, base-
line BPb and 206Pb/207Pb samples were
taken; at 0700 hr blood for 6-aminolevulinic
acid dehydratase (ALAD) was also taken.
Immediately following the 0700 hr
blood drawing, subjects consumed approxi-
mately 100 ml ofsherry. An initial control
hospitalization involved the administration
of a glass of sherry obtained directly from
the original bottle, with a lead content of
0.28 pmol/l. During a second admission,
subjects drank sherry that had been stored
for 3 years in a lead crystal decanter and
had reached a lead concentration of 14.24
pmol/l; a dose of 1.21 plmol Pb/70 kg body
weight (250 pg Pb/70 kg) was adminis-
tered. Blood samples for 206Pb/207Pb and
BPb were then taken at intervals over the
next 48 hrs. Urine samples were also col-
lected at intervals before and after ingestion.
The subjects received no breakfast and
had a standardized liquid lunch at noon. At
1700 hr on day 2, they received a standard-
ized dinner, followed by a standardized
breakfast, lunch, and dinner on day 3. All
meals were prepared in duplicate and one
portion was homogenized and frozen for
analysis; meals were unremarkable for lead
content (all <0.5 ppm Pb dryweight).
The ratio of206Pb/207Pb and total lead
content were simultaneously measured in
the blood and the urine. An appropriate
quantity of205Pb was added as an internal
standard to each blood sample, which was
then decomposed by boiling in concentrat-
ed HNO3. The solution was evaporated to
dryness and the residue charred at 250°C.
Lead was then extracted by anion exchange
chromatography and isotopically analyzed
on a Finnigan MAT 261 multicollector
mass spectrometer (12). For the admission
involving the consumption of ordinary
sherry, BPb was measured by atomic
absorption spectrophotometry according to
the method of Fernandez and Hilligoss
(13). ALAD, a measure of ongoing meta-
bolic lead toxicity, was assessed using a col-
orimetric enzyme assay (14). All other
blood and urine analyses were performed
by the CPMC laboratories.
Results
The frequency distributions of blood
206Pb/207Pb ratios for subjects screened in
New York, Brisbane, and Glasgow are illus-
trated in Figure 1. Most New York subjects
had blood 206Pb/207Pb ratios of 1.195 or
higher; those who had lower ratios typically
had spent a considerable portion of their
lives outside the United States. Australian
subjects had the lowest 206Pb/207Pb ratios,
ranging from 1.095 to 1.145, while Scottish
subjects had only slightly higher values,
ranging from 1.105 to 1.155.
The demographic characteristics of the
six New York subjects selected for the wine
ingestion study are presented in Table 1.
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Figure 1. Frequency distribution of 206Pb/207Pb isotope ratios in normal volunteers from (A) Columbia
University, NewYork, (B) Brisbane, Australia, and (C) Glasgow, Scotland.
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Prior to the ingestion of sherry that had
been in a lead-crystal decanter (206Pb/207Pb
= 1.078), the mean BPb was 0.10 pmol/l
and the mean 206Pb/207Pb ratio was 1.202.
After consumption of the sherry, the BPb
rose and the 206Pb/207Pb ratio fell to attain
values in the range 1.118-1.150 at 48 hr,
bracketing the value (1.135) at which min-
imum error magnification occurs in the
isotope dilution equation; data from a typi-
cal subject are presented in Figure 2. These
changes were essentially complete by 24 hr,
at which time the mean BPb had risen sig-
nificantly to 0.18 pmol/l (p = 0.0003) and
the mean blood 206Pb/207Pb ratio had fall-
en to 1.137 (p = 0.0001). The isotopic
ratio oflead in urine (measured in two sub-
jects) also fell rapidly, reflecting the elimi-
nation of trace amounts of the crystal-
derived lead. Red cell ALAD activity fell
from 4520 to 4183 units, but this change
did not achieve statistical significance. In
contrast, neither BPb (Table 1), blood
206Pb/207Pb ratio, nor ALAD changed sig-
nificantly after the consumption of sherry
obtained from the original bottle.
On average, by 24 hr, 38.4% of the
administered lead dose was in the blood
compartment. Bioavailability is traditional-
ly estimated by comparing the kinetics of
an oral dose to those of an intravenous
dose. Previous studies ofintravenous 203Pb
(15) indicate that at 24 hr, 55% of an
administered dose is still in the blood com-
partment. In this manner, we estimated the
mean fraction oflead absorbed from sherry
to be 70%. The range was wide, with indi-
vidual values for bioavailability of 96, 83,
77, 71, 47, and 46%.
Discussion
Historically, lead has found its way into
wines due to its use as a sweetener and from
products such as leaden kettles, distillation
devices, basins for mulling wine, lead-glazed
pottery, and lead cups (16). We know ofno
case reports attributing lead toxicity to lead
crystal glassware, although cases involving
contamination from other sources have
been reported (17). Epidemiologic studies
have found a dose-response relationship
between alcohol consumption and BPb
(18-22); wine consumption has been
reported as a specific risk factor (18,19).
This is not surprising as lead concentrations
in wines reportedly range from 0.14 to 1.21
pmol/l, with a mean of 0.42 pmol/l (23).
Lead concentrations increase dramatically
when lead foil caps (24) or lead-crystal
glasses and decanters are used (3).
Baseline lead intake from sources
including air, food, water, beverages, and
dust has been estimated to be approximate-
ly 3.09 nmol/kg/day in adult females and
3.67 nmol/kg/day in adult males (25). The
recent (1988-1991) U.S. National Health
and Nutrition Examination Survey report-
ed mean BPbs of0.12 and 0.19 pmol/l for
those aged 20-49 and 50-69 years, respec-
tively (26). The contribution of lead from
any particular source to BPb is obviously
related to the dose ingested, the fraction
absorbed, and the regularity of ingestion.
Estimates of approximately 0.10 pmol/l
BPb for each 0.48 pmol/day ofdietary lead
intake, and 0.29 pmol/l BPb for each 0.48
pmol/l of lead in the water supply have
been reported (27); these estimates assume
repeated daily ingestion. Several investiga-
tors have concluded that among regular
wine drinkers, lead intake from wine may
exceed that from diet, water, air, and dust
combined (23,24,27,28). We concur, and
conclude that for a 70-kg subject, a single
dose of 0.48 pmol of lead in sherry will
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Figure 2. Change in blood lead after ingestion of sherry containing 1.21 pmol/Pb/70 kg body weight. By
stable isotope dilution, we differentiated the relative contributions of wine lead and endogenous lead to
total blood lead.
Table 1. Demographics andfindings ofthe study
Control Lead crystal hospitalization
BPb (pmol/l)a BPb (pmol/l)b 206Pb/207Pb
Subject Age (years) Weight (kg) Race Gender Start 24 hr Dose Pb (pmol) Start 24 hr Start 24 hr % Absorbed
1 24 60.6 White F 0.16 0.16 1.04 0.17 0.29 1.206 1.148 96
2 23 58.2 Black F 0.09 0.07 1.00 0.06 0.16 1.202 1.120 83
3 28 48.0 Asian F 0.06 0.07 0.83 0.07 0.14 1.204 1.144 46
4 26 73.5 White M 0.10 0.10 1.26 0.10 0.19 1.199 1.135 77
5 24 80.0 Black M 0.11 0.11 1.38 0.08 0.14 1.196 1.142 47
6 24 60.0 Black F 0.09 0.11 1.03 0.09 0.17 1.202 1.135 71
Mean 25 63.4 0.10 0.10 1.09 0.10 0.18* 1.202 1.137** 70
aAnalyzed by atomic absorption spectrophotometry.
bAnalyzed by isotope dilution mass spectrometry.
*p= 0.0003, compared to starting BPb.
**p= 0.0001, compared to starting206Pb/203Pb ratio.
Volume 104, Number2, February 1996 * Environmental Health Perspectives 178Articles * Bioavailability oflead
induce a rise in BPb ofapproximately 0.05
pmol/l. The probability that one might
ingest a sufficient dose to induce clinically
recognizable plumbism is small, but not
zero, as beverages with more than 96.52
pmol/l have been found in homes (2).
Strictly speaking, our study has exam-
ined the bioavailability ofthe lead attribut-
able to lead crystal. It is possible that the
bioavailability of wine lead derived from
other sources might be slightly different.
Also, due to cost constraints, we could not
evaluate the impact offood on the bioavail-
ability oflead in wine.
Our subjects were carefully screened to
have initial BPbs of<0.24 pmol/l and were
administered a dose oflead that would not
cause the BPb to rise above 0.48 pmol/l,
even if absorption were complete and
instantaneous. Through this approach, the
stable isotope dilution method can also
readily be applied to the study of lead in
other matrices.
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